As Moderna expands its mRNA vaccine pipeline to target Epstein-Barr, shingles, cancer and autoimmune diseases, scientists warn the company’s COVID-19 shots may be suppressing immune function, reactivating latent viruses and potentially causing the very conditions their new products aim to prevent.

During its Vaccines Day Event for investors on March 28, Moderna announced progress on multiple mRNA-based vaccines and therapeutic candidates in its “pipeline.”

Three vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV, chickenpox and shingles) and Norovirus are advancing to “pivotal late-stage development,” the company said.

Moderna also announced that the U.S. Food and Drug Administration (FDA) is expected to approve its respiratory syncytial virus (RSV) vaccine mRNA-1345 for older adults. This is part of an expected $52 billion market for Moderna’s infectious disease vaccines.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.